COVID-19: US FDA includes ventilator developed by NASA in emergency use authorisation (EUA)

The US Food and Drug Administration (FDA) included under the ventilator emergency use authorization (EUA), a ventilator developed by the National Aeronautics and Space Administration (NASA) to treat covid-19 patients.

The ventilator was added to the list of EUA (emergency use authorization) in response to concerns relating to insufficient supply and availability of FDA-cleared ventilators for use in health care settings to treat patients during the COVID-19 pandemic.

FDA Commissioner Stephen M. Hahn, M.D said, “Fighting the virus and treating patients during this unprecedented global pandemic requires innovative approaches and action. It also takes an all hands-on deck approach, as demonstrated by the NASA engineers who used their expertise in spacecraft to design a ventilator tailored for very ill coronavirus patients. This example shows what we can do when everyone works together to fight COVID-19. We believe today’s action will increase availability of these life-saving medical devices. The FDA will continue to add products to this emergency use authorization, as appropriate, during this pandemic to facilitate an increase in ventilator inventory.”

NASA VITAL (Ventilator Intervention Technology Accessible Locally)was included by the FDA under the ventilator EUA. VITAL is specifically tailored for patients with novel coronavirus and lasts for three to four months by providing respiratory support for covid-19 patients that are experiencing respiratory failure. Similar to other ventilators, VITAL requires patients to be sedated and an oxygen tube inserted into their airway to breathe. The VITAL medical device does not replace current hospital ventilators, which can last years and are built to address a broader range of medical issues. The VITAL is designed to be built with components outside the current medical device supply chain and therefore does not impact the existing supply chain of currently made ventilators.

NASA Administrator Jim Bridenstine said, “This FDA authorization is a key milestone in a process that exemplifies the best of what government can do in a time of crisis. This ventilator is one of countless examples of how taxpayer investments in space exploration – the skills, expertise and knowledge collected over decades of pushing boundaries and achieving firsts for humanity – translate into advancements that improve life on Earth.”

  • Related Posts

    IPC releases draft NFI-2026 to promote rational use of medicines

    Ghaziabad:- The Indian Pharmacopoeia Commission (IPC) has taken a significant step toward strengthening public health systems with the draft release of the National Formulary of India (NFI) 2026, a comprehensive…

    Laser rescued an Imperiled Food Pipe in Sir Ganga Ram Hospital

    An Impacted Denture accidently  had lodged inside it New Delhi: In a remarkable medical achievement, doctors at Sir Ganga Ram Hospital successfully removed an impacted dental plate that had accidentally…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid